This company listing is no longer active
2GT Stock Overview
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Applied Genetic Technologies Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.34 |
52 Week High | €1.95 |
52 Week Low | €0.23 |
Beta | 1.58 |
11 Month Change | -16.91% |
3 Month Change | -11.95% |
1 Year Change | -80.63% |
33 Year Change | -87.16% |
5 Year Change | -89.91% |
Change since IPO | -96.47% |
Recent News & Updates
Recent updates
Shareholder Returns
2GT | DE Biotechs | DE Market | |
---|---|---|---|
7D | -1.2% | -0.7% | 1.1% |
1Y | -80.6% | -17.2% | 10.7% |
Return vs Industry: 2GT underperformed the German Biotechs industry which returned 7.4% over the past year.
Return vs Market: 2GT underperformed the German Market which returned -15.6% over the past year.
Price Volatility
2GT volatility | |
---|---|
2GT Average Weekly Movement | 23.2% |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2GT's share price has been volatile over the past 3 months.
Volatility Over Time: 2GT's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 102 | Sue Washer | agtc.com |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.
Applied Genetic Technologies Corporation Fundamentals Summary
2GT fundamental statistics | |
---|---|
Market cap | €12.62m |
Earnings (TTM) | -€66.98m |
Revenue (TTM) | €309.95k |
35.1x
P/S Ratio-0.2x
P/E RatioIs 2GT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2GT income statement (TTM) | |
---|---|
Revenue | US$325.00k |
Cost of Revenue | US$21.76m |
Gross Profit | -US$21.44m |
Other Expenses | US$48.80m |
Earnings | -US$70.23m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.19 |
Gross Margin | -6,596.62% |
Net Profit Margin | -21,610.46% |
Debt/Equity Ratio | 92.6% |
How did 2GT perform over the long term?
See historical performance and comparison